The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth
Open accessAbstract
Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not to our knowledge been previously described. We report the existence of a splice variant of the gene encoding vascular endothelial growth factor receptor-2 (Vegfr-2) that encodes a secreted form of the protein, designated soluble Vegfr-2 (sVegfr-2), that inhibits developmental and reparative lymphangiogenesis by blocking Vegf-c function. Tissue-specific loss of sVegfr-2 in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of sVegfr-2 inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring sVegfr-2 thus acts as a molecular uncoupler of blood and lymphatic vessels; modulation of sVegfr-2 might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema (pages 993–994)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Cao, R., Eriksson, A., Kubo, H., Alitalo, K., Cao, Y., & Thyberg, J. (2004) · Circulation Research · doi:10.1161/01.res.0000118600.91698.bb · Cited by 324
Waterborne Infectious DiseasesCould They Be Consigned to History?
Fenwick, A. (2006) · Science · doi:10.1126/science.1127184 · Cited by 252
Cited by
Signal transduction by vascular endothelial growth factor receptors
Koch, S., Tugues, S., Li, X., Gualandi, L., & Claesson-Welsh, L. (2011) · Biochemical Journal · doi:10.1042/bj20110301 · Cited by 1,635
Lymphangiogenesis: Molecular Mechanisms and Future Promise
Tammela, T., & Alitalo, K. (2010) · Cell · doi:10.1016/j.cell.2010.01.045 · Cited by 1,441
The lymphatic vasculature in disease
Alitalo, K. (2011) · Nature Medicine · doi:10.1038/nm.2545 · Cited by 962
Hallmarks of alternative splicing in cancer
Oltean, S., & Bates, D. O. (2014) · Oncogene · doi:10.1038/onc.2013.533 · Cited by 664
Norrin/Frizzled4 Signaling in Retinal Vascular Development and Blood Brain Barrier Plasticity
Wang, Y., Rattner, A., Zhou, Y., Williams, J., Smallwood, P. M., & Nathans, J. (2012) · Cell · doi:10.1016/j.cell.2012.10.042 · Cited by 406
Neurons Limit Angiogenesis by Titrating VEGF in Retina
Okabe, K., Kobayashi, S., Yamada, T., Kurihara, T., Tai-Nagara, I., Miyamoto, T., Mukouyama, Y.-S., Sato, T. N., Suda, T., Ema, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.025 · Cited by 311
Hos, D., Matthaei, M., Bock, F., Maruyama, K., Notara, M., Clahsen, T., Hou, Y., Le, V. N. H., Salabarria, A.-C., Horstmann, J., et al. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.07.001 · Cited by 303
Dendritic cell physiology and function in the eye
Forrester, J. V., Xu, H., Kuffová, L., Dick, A. D., & McMenamin, P. G. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00873.x · Cited by 195
Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188
Review of Ocular Immune Privilege in the Year 2010: Modifying the Immune Privilege of the Eye
Hori, J., Vega, J. L., & Masli, S. (2010) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2010.512696 · Cited by 64
Brain homeostasis: VEGF receptor 1 and 2—two unequal brothers in mind
Wittko-Schneider, I. M., Schneider, F. T., & Plate, K. H. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1279-3 · Cited by 62
VEGFR2 alteration in Alzheimer’s disease
Cho, S.-J., Park, M. H., Han, C., Yoon, K., & Koh, Y. H. (2017) · Scientific Reports · doi:10.1038/s41598-017-18042-1 · Cited by 61
Common variants upstream of KDR encoding VEGFR2 and in TTC39B associate with endometriosis
Steinthorsdottir, V., Thorleifsson, G., Aradottir, K., Feenstra, B., Sigurdsson, A., Stefansdottir, L., Kristinsdottir, A. M., Zink, F., Halldorsson, G. H., Munk Nielsen, N., et al. (2016) · Nature Communications · doi:10.1038/ncomms12350 · Cited by 48
Puranen, J., Koponen, S., Nieminen, T., Kanerva, I., Kokki, E., Toivanen, P., Urtti, A., Ylä-Herttuala, S., & Ruponen, M. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109237 · Cited by 9
Antiangiogenesis Effect of Albendazole on the Cornea
Cho, Y. K., Shin, E. Y., Uehara, H., & Ambati, B. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0103 · Cited by 7
Self-citation
Metadata
- Authors
- Albuquerque, R. J. C., Hayashi, T., Cho, W. G., Kleinman, M. E., Dridi, S., Takeda, A., Baffi, J. Z., Yamada, K., Kaneko, H., Green, M. G., Chappell, J., Wilting, J., Weich, H. A., Yamagami, S., Amano, S., Mizuki, N., Alexander, J. S., Peterson, M. L., Brekken, R. A., Hirashima, M., Capoor, S., Usui, T., Ambati, B. K., & Ambati, J.
- Venue
- Nature Medicine
- Published
- 2009-08-09
- Volume
- 15
- Issue
- 9
- Pages
- 1023-1030
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2037626596
- Cited by
- 357
- References
- 5
- FWCI
- 14.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.